Compositions comprising modified biologically active polypeptides
First Claim
1. A composition comprising a soluble form of a modified polypeptide comprising a biologically active polypeptide linked to an accessory polypeptide, wherein said accessory polypeptide comprises at least 40 contiguous amino acids and further wherein(a) the accessory polypeptide consists of three types of amino acids selected from a group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the accessory polypeptide;
- and(b) at least 50% of the amino acids are devoid of secondary structure as determined by Chou-Fasman algorithm,and wherein said modified polypeptide has an increased solubility in a host cell in which the modified polypeptide is expressed as compared to biologically active polypeptide lacking said accessory polypeptide.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
164 Citations
12 Claims
-
1. A composition comprising a soluble form of a modified polypeptide comprising a biologically active polypeptide linked to an accessory polypeptide, wherein said accessory polypeptide comprises at least 40 contiguous amino acids and further wherein
(a) the accessory polypeptide consists of three types of amino acids selected from a group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the accessory polypeptide; - and
(b) at least 50% of the amino acids are devoid of secondary structure as determined by Chou-Fasman algorithm, and wherein said modified polypeptide has an increased solubility in a host cell in which the modified polypeptide is expressed as compared to biologically active polypeptide lacking said accessory polypeptide. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- and
Specification